Bezafibrate prevents hepatic stellate cell activation and fibrogenesis in a murine steatohepatitis model, and suppresses fibrogenic response induced by transforming growth factor-β1 in a cultured stellate cell line

Hepatology Research

Volumn 38, Issue 10, 2008, Pages 1026-1039

  Nakano, Shigeru ^a   Nagasawa, Tatsuya ^a   Ijiro, Tomoyuki ^a   Inada, Yoichi ^a   Tamura, Toru ^a   Maruyama, Kazuyasu ^a   Kuroda, Junji ^a   Yamazaki, Yoshinobu ^a   Kusama, Hiroshi ^a   Shibata, Nobuo ^a  

^a KISSEI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Bezafibrate; Hepatic fibrosis; Hepatic stellate cell activation; Methionine and choline deficient diet; Non alcoholic steatohepatitis; Peroxisome proliferator activated receptors

Indexed keywords

[2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; ADIPONECTIN; ALANINE AMINOTRANSFERASE; BEZAFIBRATE; CHEMOKINE; CHOLINE; CYTOKINE; FENOFIBRIC ACID; MESSENGER RNA; METHIONINE; PIOGLITAZONE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRANSFORMING GROWTH FACTOR BETA1; TRIACYLGLYCEROL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL CULTURE; CELL LINE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; ENZYME REPRESSION; FATTY ACID OXIDATION; FATTY LIVER; FIBROGENESIS; GENE EXPRESSION; IN VITRO STUDY; LIVER FIBROSIS; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PRIORITY JOURNAL; STELLATE CELL;

EID: 51349140361     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2008.00363.x     Document Type: Article

References (55)

1. Diehl AM. Nonalcoholic steatohepatitis. Semin Liver Dis 1999; 19: 221-9.
2. Marchesini G, Bugianesi E, Forlani G et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-23.
3. Pagano G, Pacini G, Musso G et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: Further evidence for an etiologic association. Hepatology 2002; 35: 367-72.
4. Day CP, James OF. Steatohepatitis: A tale of two "hits"? Gastroenterology 1998; 114: 842-5.
5. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003; 37: 1202-19.
6. Olaso E, Friedman SL. Molecular regulation of hepatic fibrogenesis. J Hepatol 1998; 29: 836-47.
7. Friedman SL. Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N Engl J Med 1993; 328: 1828-35.
8. Maher JJ, McGuire RF. Extracellular matrix gene expression increases preferentially in rat lipocytes and sinusoidal endothelial cells during hepatic fibrosis in vivo. J Clin Invest 1990; 86: 1641-8.
9. Bissell DM. Lipocyte activation and hepatic fibrosis. Gastroenterology 1992; 102: 1803-5.
10. 1 in human fat-storing cells. Gastroenterology 1993; 105: 245-53.
11. Tanaka T, Masuzaki H, Ebihara K et al. Transgenic expression of mutant peroxisome proliferator-activated receptor γ in liver precipitates fasting-induced steatosis but protects against high-fat diet-induced steatosis in mice. Metabolism 2005; 54: 1490-8.
12. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Sponseller CA, Hampton K, Bacon BR. Interim results of a pilot study demonstrating the early effects of the PPAR-γ ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis. J Hepatol 2003; 38: 434-40.
13. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone. Hepatology 2003; 38: 1008-17.
14. Galli A, Crabb D, Price D et al. Peroxisome proliferator-activated receptor γ transcriptional regulation is involved in platelet-derived growth factor-induced proliferation of human hepatic stellate cells. Hepatology 2000; 31: 101-8.
15. Marra F, Efsen E, Romanelli RG et al. Ligands of peroxisome proliferator-activated receptor γ modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology 2000; 119: 466-78.
16. Kon K, Ikejima K, Hirose M et al. Pioglitazone prevents early-phase hepatic fibrogenesis caused by carbon tetrachloride. Biochem Biophys Res Commun 2002; 291: 55-61.
17. Galli A, Crabb DW, Ceni E et al. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 2002; 122: 1924-40.
18. Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: From orphan receptors to drug discovery. J Med Chem 2000; 43: 527-50.
19. Tenenbaum A, Motro M, Fisman EZ et al. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation 2004; 109: 2197-202.
20. Tenenbaum A, Fisman EZ, Boyko V et al. Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate. Arch Intern Med 2006; 166: 737-41.
21. Saibara T, Onishi S, Ogawa Y, Yoshida S, Enzan H. Bezafibrate for tamoxifen-induced non-alcoholic steatohepatitis. Lancet 1999; 353: 1802.
22. Toyama T, Nakamura H, Harano Y et al. PPARα ligands activate antioxidant enzymes and suppress hepatic fibrosis in rats. Biochem Biophys Res Commun 2004; 324: 697-704.
23. Ip E, Farrell G, Hall P, Robertson G, Leclercq I etal. Administration of the potent PPARα agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice. Hepatology 2004; 39: 1286-96.
24. George J, Pera N, Phung N, Leclercq I, Yun Hou J, Farrell G. Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. J Hepatol 2003; 39: 756-64.
25. Ip E, Farrell GC, Robertson G, Hall P, Kirsch R, Leclercq I. Central role of PPARα-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology 2003; 38: 123-32.
26. McCuskey RS, Ito Y, Robertson GR, McCuskey MK, Perry M, Farrell GC. Hepatic microvascular dysfunction during evolution of dietary steatohepatitis in mice. Hepatology 2004; 40: 386-93.
27. y mice. Hepatol Res 2006; 36: 217-28.
28. Weltman MD, Farrell GC, Liddle C. Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology 1996; 111: 1645-53.
29. Folch J, Lees M, Stanley GHS. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 1957; 226: 497-509.
30. Tokiwa T, Yata Y, Takahara T et al. SV40 large T antigen immortalization of rat hepatic stellate-like cells. In Vitro Cell Dev Biol Anim 1999; 35: 246-7.
31. Yutaka Y, Tokiwa T, Takahara T, Zhang LP, Watanabe A. Characterization of immortalized rat hepatic stellate cell lines transfected with SV40 T antigen. Hepatol Res 1999; 14: 239-44.
32. Nagasawa T, Inada Y, Nakano S et al. Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARä agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. Eur J Pharmacol 2006; 536: 182-91.
33. Chavey C, Mari B, Monthouel MN et al. Matrix metalloproteinases are differentially expressed in adipose tissue during obesity and modulate adipocyte differentiation. J Biol Chem 2003; 278: 11888-96.
34. Ding X, Saxena NK, Lin S, Xu A, Srinivasan S, Anania FA. The roles of leptin and adiponectin: A novel paradigm in adipocytokine regulation of liver fibrosis and stellate cell biology. Am J Pathol 2005; 166: 1655-69.
35. Kuzuya M, Kanda S, Sasaki T et al. Deficiency of gelatinase a suppresses smooth muscle cell invasion and development of experimental intimal hyperplasia. Circulation 2003; 108: 1375-81.
36. Trogan E, Choudhury RP, Dansky HM, Rong JX, Breslow JL, Fisher EA. Laser capture microdissection analysis of gene expression in macrophages from atherosclerotic lesions of apolipoprotein E-deficient mice. Proc Natl Acad Sci USA 2003; 99: 2234-9.
37. Chianale J, Vollrath V, Wielandt AM et al. Fibrates induce mdr2 gene expression and biliary phospholipids secretion in the mouse. Biochem J 1996; 314: 781-6.
38. Peters JM, Aoyama T, Burns AM, Gonzalez FJ. Bezafibrate is a dual ligand for PPARα and PPARβ: Studies using null mice. Biochim Biophys Acta 2003; 1632: 80-9.
39. Kjorholt C, Akerfeldt MC, Biden TJ, Laybutt DR. Chronic hyperglycemia, independent of plasma lipid levels, is sufficient for the loss of,-cell differentiation and secretory function in the db/db mouse model of diabetes. Diabetes 2005; 54: 2755-63.
40. Shoda J, Okada K, Inada Y et al. Bezafibrate induces multidrug-resistance P-Glycoprotein 3 expression in cultured human hepatocytes and humanized livers of chimeric mice. Hepatol Res 2007; 37: 548-56.
41. Shoda J, Inada Y, Tsuji A et al. Bezafibrate stimulates canalicular localization of NBD-labeled PC in HepG2 cells by PPARα-mediated redistribution of ABCB4. J Lipid Res 2004; 45: 1813-25.
42. Motojima K, Passilly P, Peters JM, Gonzalez FJ, Latruffe N. Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor α and γ activators in a tissue- and inducer-specific manner. J Biol Chem 1998; 273: 16710-14.
43. Asayama K, Sandhir R, Sheikh FG, Hayashibe H, Nakane T, Singh I. Increased peroxisomal fatty acid,-oxidation and enhanced expression of peroxisome proliferator-activated receptor-α in diabetic rat liver. Mol Cell Biochem 1999; 194: 227-34.
44. Delerive P, Gervois P, Fruchart JC, Staels B. Induction of IκBα expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-α activators. J Biol Chem 2000; 275: 36703-7.
45. Yoneda M, Endo H, Nozaki Y et al. Life style-related diseases of the digestive system: Gene expression in nonalcoholic steatohepatitis patients and treatment strategies. J Pharmacol Sci 2007; 105: 151-6.
46. Nakano S, Inada Y, Masuzaki H et al. Bezafibrate regulates the expression and enzyme activity of 11β-hydroxysteroid dehydrogenase type 1 in murine adipose tissue and 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab 2007; 292: E1213-22.
47. Czaja MJ. Liver injury in the setting of steatosis: Crosstalk between adipokine and cytokine. Hepatology 2004; 40: 19-22.
48. Kamada Y, Tamura S, Kiso S et al. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology 2003; 125: 1796-807.
49. Hellemans K, Michalik L, Dittie A et al. Peroxisome proliferator-activated receptor-β signaling contributes to enhanced proliferation of hepatic stellate cells. Gastroenterology 2003; 124: 184-201.
50. Leclercq IA, Lebrun VA, Starkel P, Horsmans YJ. Intrahepatic insulin resistance in a murine model of steatohepa titis: Effect of PPARγ agonist pioglitazone. Lab Invest 2007; 87: 56-65.
51. Ota T, Takamura T, Kurita S et al. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. Gastroenterology 2007; 132: 282-93.
52. Kawaguchi K, Sakaida I, Tsuchiya M, Omori K, Takami T, Okita K. Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient 1-amino acid-defined diet. Biochem Biophys Res Commun 2004; 315: 187-95.
53. Uto H, Nakanishi C, Ido A et al. The peroxisome proliferator-activated receptor-γ agonist, pioglitazone, inhibits fat accumulation and fibrosis in the livers of rats fed a choline-deficient, 1-amino acid-defined diet. Hepatol Res 2005; 32: 235-42.
54. y mice exhibit increased hepatic PPARγ1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones. J Hepatol 2001; 35: 17-23.
55. Rinella ME, Green RM. The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. J Hepatol 2004; 40: 47-51.